- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Novartis Drops Experimental Amyotrophic Lateral Sclerosis Drug After Mid-Stage Trial Failure

Bengaluru: Novartis has halted development of an experimental drug for amyotrophic lateral sclerosis after it failed to meet goals in a mid-stage study, marking the latest disappointment for the Swiss drugmaker this year.
This follows an earlier setback for a closely watched heart drug, last week's late-stage failure of a muscle-wasting drug, and the halt of eight of 10 studies for its rap-cel cell therapy this month after three patient deaths. These developments have intensified investor scrutiny of its pipeline.
Endpoints News and Bloomberg News reported the news earlier on Wednesday, which the company later confirmed in an emailed statement to Reuters, saying it was discontinuing development of the drug VHB937.
The drug, also called lifonebart, was being studied in patients with ALS, also called Lou Gehrig's disease. It is a neurodegenerative condition that affects how nerve cells communicate with muscles and leads to muscle weakness that worsens over time.
The company's U.S.-listed shares were marginally up.
The drug failed to meet both main and secondary goals in the mid-stage trial, which was evaluating the efficacy and safety of VHB937 in participants with early-stage ALS within two years of symptom onset.
The study had enrolled 251 patients, according to clinicaltrials.gov.
The drug aims to stabilize TREM2, a protein that helps regulate immune responses, inflammation and waste clearance in the brain.
Companies have been trying to develop TREM2 drug candidates but have faced failures. In 2024, Alector said its experimental drug failed in a mid-stage trial.
Novartis is also studying the drug in patients with Alzheimer's disease, a progressive brain disorder that slowly robs memory.
The clinical trials website shows the company is recruiting patients for the mid-stage trial.
Sheeba Farhat Joined Medical Dialogues in 2018 to report on the latest Education news. A Graduate of the University of Delhi, she specializes in covering stories related to Medical Education updates. For inquiries or further information, you can reach her at editorial@medicaldialogues.in.

